LivaNova (LIVN) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

LivaNova (LIVN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

47.58

0.26 (0.55%)

At close: Jan 14, 2025, 3:59 PM

49.50

4.04%

Pre-market Jan 15, 2025, 04:20 AM EST

undefined% (undefined)

Bid	42.56
Market Cap	2.58B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.43
PE Ratio (ttm)	110.65
Forward PE	n/a
Analyst	Buy

Ask	53
Volume	467,972
Avg. Volume (20D)	498,718
Open	47.54
Previous Close	47.32
Day's Range	47.05 - 48.18
52-Week Range	43.15 - 64.47
Beta	undefined

About LIVN

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The ...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Oct 19, 2015

Employees 2,900

Stock Exchange NASDAQ

Ticker Symbol LIVN

Website https://www.livanova.com

Analyst Forecast

According to 6 analyst ratings, the average rating for LIVN stock is "Buy." The 12-month stock price forecast is $71, which is an increase of 49.22% from the latest price.

Buy 83.33%

Hold 16.67%

Sell 0.00%

Stock Forecasts

Next Earnings Release

LivaNova is scheduled to release its earnings on Feb 19, 2025, before market opens.
Analysts project revenue of $324.11M, reflecting a 4.52% YoY growth and earnings per share of 0.8, making a -8.05% decrease YoY.

Why Price Moved

2 months ago · Source

+2.3%

LivaNova shares are trading higher after the compa... Unlock content with Pro Subscription

3 months ago · Source

+4.53%

LivaNova shares are trading higher after Baird upgraded the stock from Neutral to Outperform and raised its price target from $55 to $66.

News

2 weeks ago · zacks.com

5 Beaten-Down MedTech Stocks Set to Rebound in 2025

Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape.

4 weeks ago · businesswire.com

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced that Brain Stimulation published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study.

1 month ago · businesswire.com

LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, taking place Dec. 6-10 in Los Angeles.

1 month ago · zacks.com

Wall Street Analysts Predict a 37.2% Upside in LivaNova (LIVN): Here's What You Should Know

The mean of analysts' price targets for LivaNova (LIVN) points to a 37.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst...

1 month ago · zacks.com

LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint

LIVN's aura6000 significantly increases responder rates. The device also reduces AHI and ODI levels.

2 months ago · businesswire.com

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.

2 months ago · zacks.com

LivaNova (LIVN) Upgraded to Strong Buy: What Does It Mean for the Stock?

LivaNova (LIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

2 months ago · zacks.com

How Much Upside is Left in LivaNova (LIVN)? Wall Street Analysts Think 38.2%

The consensus price target hints at a 38.2% upside potential for LivaNova (LIVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

2 months ago · zacks.com

Best Momentum Stocks to Buy for November 7th

KRUS, FTDR and LIVN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 7, 2024.

2 months ago · zacks.com

New Strong Buy Stocks for November 7th

MCO, EBS, LIVN, FTDR and KRUS have been added to the Zacks Rank #1 (Strong Buy) List on November 7, 2024.

2 months ago · zacks.com

Best Value Stocks to Buy for November 7th

JWN and LIVN made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 7, 2024.

2 months ago · seekingalpha.com

LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript

LivaNova PLC (NASDAQ:LIVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President-Corporate Development & IT Vladimir Makatsaria - Chi...

2 months ago · zacks.com

LivaNova (LIVN) Tops Q3 Earnings and Revenue Estimates

LivaNova (LIVN) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.73 per share a year ago.

2 months ago · businesswire.com

LivaNova Reports Third-Quarter 2024 Results

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance.

2 months ago · seekingalpha.com

LivaNova: Economics Should Start Making Sustained Improvements

LivaNova's Essenz product drives revenue growth, with successful rollout and premium pricing boosting guidance despite tough comparisons into the end of the year. Neuromodulation revenues, particularl...